Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBS | P35520 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.80 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.80 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.80 |
| ▸ | APP | P05067 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
| ▸ | GABRP | O00591 | 3/20 | 0.67 |
| ▸ | GABRD | O14764 | 3/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.67 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.67 |
| ▸ | GABRE | P78334 | 3/20 | 0.67 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Agathisflavone SCHEMBL30637380 | 1.00 | CBS (1.00) | CBSPTPN1CDK5CDK5R1APP | |
| SCHEMBL30442786 | 0.91 | CBS (0.82) | CBSPTPN1CDK5CDK5R1APP | |
| SCHEMBL24088771 | 0.91 | CBS (0.82) | CBSPTPN1CDK5CDK5R1APP | |
| Cupressuflavone SCHEMBL31670258 | 0.89 | CBS (1.00) | CBSPTPN1CDK5CDK5R1APP | |
| Cupressuflavone SCHEMBL505213 | 0.89 | CBS (1.00) | CBSPTPN1CDK5CDK5R1APP | |
| Cupressuflavone SCHEMBL4650575 | 0.88 | CBS (0.97) | CBSPTPN1CDK5CDK5R1APP | |
| SCHEMBL15899618 | 0.85 | APP (0.77) | CBSPTPN1CDK5CDK5R1APP | |
| SCHEMBL25858984 | 0.85 | CBS (0.73) | CBSPTPN1CDK5CDK5R1APP | |
| SCHEMBL30646164 | 0.84 | APP (1.00) | CBSPTPN1CDK5CDK5R1APP | |
| SCHEMBL27350769 | 0.84 | APP (1.00) | CBSPTPN1CDK5CDK5R1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| CN-103221056-A | Electronically Modified Reaction Intermediates | MARKOU DEMETRIOS | 2013-07-24 | — | — | CN | claimed |
| EP-2603225-A2 | ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | Markou, Demetrios (US) | 2013-06-19 | — | — | EP | claimed |
| WO-2012024196-A2 | A NOVEL METHOD FOR CREATING, SUSPENDING AND STABILIZING ELECTRONICALLY MODIFIED REACTION INTERMIDEATES | MARKOU DEMETRIOS (US) | 2012-02-23 | — | — | WO | claimed |
| US-20120039796-A1 | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients | MARKOU DEMETRIOS (US) | 2012-02-16 | — | — | US | claimed |
| WO-2009023803-A2 | MODULATED RELEASE FORMULATION FOR THE DELIVERY OF ONE OR MORE MEDICAMENTS | ABBOTT RESPIRATORY LLC (US) | 2009-02-19 | — | — | WO | claimed |
| CN-101049301-A | Pharmaceutical preparation of biflavone compound for anti gout | HUIBEI COLLEGE OF CHINESE MEDI (CN) | 2007-10-10 | — | — | CN | claimed |
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | ADVANCED LIFE SCIENCES, INC. | 2002-06-06 | — | — | US | claimed |
| US-6399654-B1 | ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID | ADVANCED LIFE SCIENCES, INC. | 2002-06-04 | — | — | US | claimed |
| WO-1998046238-A1 | BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT | MEDICHEM RESEARCH, INC. (US) | 1998-10-22 | — | — | WO | claimed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | claimed |
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-07-17 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240390393-A1 | BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240307413-A1 | BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE | EMORY UNIVERSITY (US) | 2024-09-19 | — | — | US | disclosed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | disclosed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | CBS 3379/4885PTPN1 1321/4885CDK5 1699/4885 |
| US-20240390393-A1 | BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE | BROX, C5, SYMPK | CBS 237/4885PTPN1 2016/4885CDK5 2934/4885 |
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | HK2, GYS2, HK1 | CBS 3171/4885PTPN1 1427/4885CDK5 2719/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CBS 1776/4885PTPN1 4387/4885CDK5 4599/4885 |
| US-20240307413-A1 | BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE | BROX, C5, SYMPK | CBS 237/4885PTPN1 2016/4885CDK5 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.